These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2074385)

  • 41. [Cisplatin and ovarian carcinoma--early detection of cisplatin-induced nephrotoxicity].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):888-96. PubMed ID: 4040542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Renal toxicity by intraperitoneal administration of CDDP].
    Chen JT; Yamashiro T; Shimizu Y; Kuo TC; Nakayama K; Teshima H; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 May; 40(5):534-40. PubMed ID: 3385274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pharmacokinetics of CDDP by the route of administration in patients with ovarian cancer].
    Takada M; Usui N; Suzuki M; Furugen Y; Yamamoto T
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Feb; 45(2):99-105. PubMed ID: 8429253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effect, toxicity and tissue concentration in the clinical use of cis-diamminedichloroplatinum (II)].
    Kodama S; Obata N; Hando T; Ikarashi T; Goto A; Takeuchi S
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 May; 37(5):683-90. PubMed ID: 4039742
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Intraperitoneal (Ip) high-dose cisplatinum (CDDP) chemotherapy in patients with advanced ovarian cancer].
    Noda T; Saitoh S; Ando Y; Nakanishi A; Maruya C; Yoh S; Hino K; Kiyozuka Y; Ichijo M
    Nihon Gan Chiryo Gakkai Shi; 1985 May; 20(4):797-807. PubMed ID: 4056550
    [No Abstract]   [Full Text] [Related]  

  • 46. Intermittent cisplatin therapy for stage-III ovarian cancer patients following clinical remission.
    Umesaki N; Tanaka T; Muso H; Kawamura N; Kanaoka Y; Honda K; Deguchi M; Ishiko O; Ogita S
    Gynecol Obstet Invest; 1999; 47(2):139-43. PubMed ID: 9949286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical evaluation of intermittent administration of CDDP in advanced ovarian cancer].
    Umesaki N; Kou B; Ooshika Y; Yamamoto K; Sugawa T
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):191-5. PubMed ID: 2498440
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Significance of intermittent CDDP therapy for improving long-term prognosis in patients with advanced ovarian cancer].
    Umesaki N; Yamamoto A; Nakano M; Matsumoto Y; Tsuda K; Kawabata M; Sugawa T
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Dec; 43(12):1623-30. PubMed ID: 1744459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
    Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
    Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
    Gershenson DM; Morris M; Burke TW; Levenback C; Kavanagh JJ; Fromm GL; Silva EG; Warner D; Wharton JT
    Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The effect on prognosis and the adverse drug reaction of intermittent cisplatin therapy in advanced ovarian cancer patients].
    Umesaki N; Matsumoto Y; Nakano M; Kawabata M; Sugawa T
    Nihon Gan Chiryo Gakkai Shi; 1990 Dec; 25(12):2758-66. PubMed ID: 2074385
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
    Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
    Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.